|
||||
Delaware
|
|
000-28386
|
|
91-1533912
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
|
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Name
|
|
Title
|
|
2018 Non-Equity Incentive Payment
|
|
|
2019 Base Salary
(1)
|
|
|
Option Grant (in shares)
|
|
|||
Adam R. Craig, M.D., Ph.D.
|
|
President and Chief Executive Officer
|
|
$
|
311,575
|
|
|
$
|
600,000
|
|
|
|
1,300,000
(2)
|
|
Bruce J. Seeley
|
|
Executive Vice President, Chief Operating Officer
|
|
|
164,000
|
|
|
|
422,300
|
|
|
|
400,000
|
|
David H. Kirske
|
|
Executive Vice President, Chief Financial Officer and Secretary
|
|
|
122,500
|
|
|
|
360,500
|
|
|
|
500,000
|
|
(1)
|
The 2019 base salary figures are effective as of February 19, 2019.
|
(2)
|
The grant of options to Dr. Craig is contingent upon the Company obtaining stockholder approval of a proposed increase to the number of shares issuable under the Company’s Amended and Restated 2017 Equity Incentive Plan (the “
Proposed
Plan Increase
”). The Company intends to seek stockholder approval of the Proposed Plan Increase at its 2019 annual general meeting of stockholders.
|
|
|
|
|
|
|
|
|
|
|
|
|
CTI BIOPHARMA CORP.
|
||
Date: February 22, 2019
|
|
By:
|
|
/s/ David H. Kirske
|
|
|
|
|
David H. Kirske
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|